Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus PT from Brokerages
Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus Price Target from Brokerages
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
Mural Oncology Announces Sanction of the Scheme by the High Court
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mural Oncology plc (NASDAQ: MURA)
MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
Mural Oncology (MURA) Q2 Loss Widens 49%
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Mural Oncology Announces Number of Relevant Securities in Issue
FORM 8.1(a) & (b) - Mural Oncology plc
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Mural Oncology Announces Plans to Explore Strategic Alternatives
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology to Participate in Two Upcoming Investor Conferences
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology to Present at Two Upcoming Investor Conferences
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio Value
Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)